CA3031254A1 - Levodopa and carbidopa intestinal gel and methods of use - Google Patents

Levodopa and carbidopa intestinal gel and methods of use Download PDF

Info

Publication number
CA3031254A1
CA3031254A1 CA3031254A CA3031254A CA3031254A1 CA 3031254 A1 CA3031254 A1 CA 3031254A1 CA 3031254 A CA3031254 A CA 3031254A CA 3031254 A CA3031254 A CA 3031254A CA 3031254 A1 CA3031254 A1 CA 3031254A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
active agent
carbidopa
levodopa
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3031254A
Other languages
English (en)
French (fr)
Inventor
Alexandru Deac
Ye Huang
John M. Lipari
Alexander RUGGLES
Thin Yu TUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA3031254A1 publication Critical patent/CA3031254A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3031254A 2016-07-20 2017-07-20 Levodopa and carbidopa intestinal gel and methods of use Abandoned CA3031254A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364770P 2016-07-20 2016-07-20
US62/364,770 2016-07-20
PCT/US2017/043103 WO2018017850A1 (en) 2016-07-20 2017-07-20 Levodopa and carbidopa intestinal gel and methods of use

Publications (1)

Publication Number Publication Date
CA3031254A1 true CA3031254A1 (en) 2018-01-25

Family

ID=59506369

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3031254A Abandoned CA3031254A1 (en) 2016-07-20 2017-07-20 Levodopa and carbidopa intestinal gel and methods of use

Country Status (9)

Country Link
US (4) US20180021280A1 (https=)
EP (1) EP3487479A1 (https=)
JP (3) JP2019523249A (https=)
CN (1) CN109715139A (https=)
AU (2) AU2017299710A1 (https=)
BR (1) BR112019001082A2 (https=)
CA (1) CA3031254A1 (https=)
MX (2) MX2019000849A (https=)
WO (1) WO2018017850A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
WO2021039084A1 (ja) * 2019-08-30 2021-03-04 テルモ株式会社 注射液製剤
EP4616878A1 (en) * 2024-03-15 2025-09-17 Cosmo Technologies Ltd. Cannula for rectal administration of an enema and compositions for use therewith

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
CN1901881A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增强的吸收的组合物和剂型
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
DE102006034346B4 (de) * 2006-07-25 2008-11-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum periodischen Messen der Fließgrenze von Dispersionen sowie deren Verwendung
US20150182688A1 (en) * 2013-12-31 2015-07-02 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
SE538425C2 (en) * 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
PT3782617T (pt) * 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Also Published As

Publication number Publication date
WO2018017850A1 (en) 2018-01-25
EP3487479A1 (en) 2019-05-29
JP2019523249A (ja) 2019-08-22
JP2022166217A (ja) 2022-11-01
AU2017299710A1 (en) 2019-01-31
US20180021280A1 (en) 2018-01-25
JP2025000924A (ja) 2025-01-07
US20230129413A1 (en) 2023-04-27
BR112019001082A2 (pt) 2019-04-30
US20260014108A1 (en) 2026-01-15
US20210059968A1 (en) 2021-03-04
MX2022014577A (es) 2023-01-11
CN109715139A (zh) 2019-05-03
MX2019000849A (es) 2019-09-13
AU2023203340A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US20260014108A1 (en) Levodopa and Carbidopa Intestinal Gel and Methods of Use
JP7232235B2 (ja) レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法
WO2016008546A1 (en) Aqueous formulation comprising paracetamol and ibuprofen
JP5116482B2 (ja) イオントフォレーシス用製剤
CN101553208B (zh) 甲地孕酮物质的药学稳定的混悬液
EP3097907B1 (en) A gel formulation comprising analgesic and anesthesic agents
CA2824433A1 (en) Aqueous liquid bromfenac composition having preservative efficacy
US20050158371A1 (en) Novel external agent
JP5301205B2 (ja) ゲル軟膏組成物
US20240041778A1 (en) Concentrated liquid gel formulations containing naproxen salts
EP3958845A1 (en) Pharmaceutical composition comprising amorphous sunitinib
BR112019022896A2 (pt) composição, e, métodos para produzir um comprimido de liberação modificada e para administrar uma quantidade terapeuticamente eficaz de um fármaco

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301